Izquierdo M A, Shoemaker R H, Flens M J, Scheffer G L, Wu L, Prather T R, Scheper R J
Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.
Int J Cancer. 1996 Jan 17;65(2):230-7. doi: 10.1002/(SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-H.
In addition to P-glycoprotein (Pgp), 2 proteins related to multidrug resistance (MDR) have recently been described. The Multidrug-Resistance-associated protein (MRP) is one of the ATP-binding-cassette (ABC) transporters. The Lung-Resistance Protein (LRP) is the major component of human vaults, which are newly described cellular organelles and thought to mediate intracellular transport processes. Using immunocytochemical methods, we have examined the expression of MRP and LRP among panels of human cancer-cell lines not selected for drug resistance which have been previously characterized for expression of Pgp, and in vitro response to a variety of anti-cancer drugs. Expression of MRP and LRP was observed in 47/55 (87%) and 46/59 (78%) cell lines, respectively. Statistically significant correlations were observed between expression of each of these 3 proteins and in vitro sensitivity to at least one drug classically associated with MDR. LRP showed the greatest individual predictive value, which also applied to several non-classical MDR drugs. Co-expression of 2-3 MDR-related proteins was observed in 64% of the lines and was, in general, associated with high relative levels of drug resistance. Previously identified "classic" MDR lines as well as "pan-resistant" lines concurrently expressed all 3 MDR-related proteins. Some highly drug-resistant cell lines without detectable MDRI/Pgp were found to express relatively high levels of MRP and LRP. The high prevalence of MRP and LRP expression observed in this large set of cell lines, which have not been subjected to laboratory drug selection, suggests that MDR mechanisms associated with these proteins may be widespread in human malignancies. Moreover, the overlapping of these more recently recognized MDR phenotypes with Pgp-type MDR results in a complex phenotype, the understanding of which may be of importance in the development of new drugs and design of clinical treatment protocols, particularly those seeking to employ strategies to reverse the MDR phenotype.
除P-糖蛋白(Pgp)外,最近还发现了2种与多药耐药性(MDR)相关的蛋白质。多药耐药相关蛋白(MRP)是ATP结合盒(ABC)转运蛋白之一。肺耐药蛋白(LRP)是人类穹窿体的主要成分,人类穹窿体是新发现的细胞器,被认为介导细胞内运输过程。我们采用免疫细胞化学方法,检测了未经过耐药性筛选的人类癌细胞系中MRP和LRP的表达情况,这些细胞系先前已对Pgp表达及对多种抗癌药物的体外反应进行了特征描述。在55个细胞系中有47个(87%)观察到MRP表达,在59个细胞系中有46个(78%)观察到LRP表达。这3种蛋白质中每种蛋白质的表达与对至少一种经典的与MDR相关药物的体外敏感性之间均存在统计学上的显著相关性。LRP显示出最大的个体预测价值,这也适用于几种非经典的MDR药物。在64%的细胞系中观察到2 - 3种与MDR相关蛋白质的共表达,总体上与较高的相对耐药水平相关。先前鉴定的“经典”MDR细胞系以及“泛耐药”细胞系同时表达所有3种与MDR相关的蛋白质。发现一些未检测到MDRI/Pgp的高度耐药细胞系表达相对高水平的MRP和LRP。在这一大组未经过实验室药物筛选细胞系中观察到的MRP和LRP表达的高发生率表明,与这些蛋白质相关的MDR机制可能在人类恶性肿瘤中广泛存在。此外,这些最近认识到的MDR表型与Pgp型MDR的重叠导致了一种复杂的表型,对其的理解可能在新药开发和临床治疗方案设计中具有重要意义,特别是那些寻求采用逆转MDR表型策略的方案。